[go: up one dir, main page]

BRPI0418005A - composição farmacêutica de vinflunina, utilização de uma composição, processo de preparação de uma composição e recipiente de acondicionamento - Google Patents

composição farmacêutica de vinflunina, utilização de uma composição, processo de preparação de uma composição e recipiente de acondicionamento

Info

Publication number
BRPI0418005A
BRPI0418005A BRPI0418005-4A BRPI0418005A BRPI0418005A BR PI0418005 A BRPI0418005 A BR PI0418005A BR PI0418005 A BRPI0418005 A BR PI0418005A BR PI0418005 A BRPI0418005 A BR PI0418005A
Authority
BR
Brazil
Prior art keywords
composition
preparing
vinflunine
packaging container
pharmaceutical composition
Prior art date
Application number
BRPI0418005-4A
Other languages
English (en)
Inventor
Elie Leverd
Joul Bougaret
Marie-Dominique Ibarra
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34630533&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0418005(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of BRPI0418005A publication Critical patent/BRPI0418005A/pt
Publication of BRPI0418005B1 publication Critical patent/BRPI0418005B1/pt
Publication of BRPI0418005B8 publication Critical patent/BRPI0418005B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"COMPOSIçãO FARMACêUTICA DE VINFLUNINA, UTILIZAçãO DE UMA COMPOSIçãO, PROCESSO DE PREPARAçãO DE UMA COMPOSIçãO E RECIPIENTE DE ACONDICIONAMENTO". A presente invenção refere-se a uma composição farmacêutica de vinflunina, que se apresenta sob a forma de uma solução aquosa estável e estéril de um sal hidrossolúvel de vinflunina com pH compreendida entre 3 e 4. Ela refere-se igualmente ao processo de preparação desta composição e sua utilização como medicamento destinado a uma administração parenteral mp tratamento do câncer.
BRPI0418005A 2003-12-23 2004-12-17 composição farmacêutica de dinflunina, utilização de uma composição, e, processo de preparação de uma composição BRPI0418005B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0315312A FR2863891B1 (fr) 2003-12-23 2003-12-23 Composition pharmaceutique de vinflunine destinee a une administration parentale, procede de preparation et utilisation
PCT/FR2004/003287 WO2005070425A1 (fr) 2003-12-23 2004-12-17 Composition pharmaceutique de vinflunine destinee a une administration parenterale, procede de preparation et utilisation

Publications (3)

Publication Number Publication Date
BRPI0418005A true BRPI0418005A (pt) 2007-04-17
BRPI0418005B1 BRPI0418005B1 (pt) 2019-11-26
BRPI0418005B8 BRPI0418005B8 (pt) 2021-05-25

Family

ID=34630533

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0418005A BRPI0418005B8 (pt) 2003-12-23 2004-12-17 composição farmacêutica de dinflunina, utilização de uma composição, e, processo de preparação de uma composição

Country Status (35)

Country Link
US (1) US20070155768A1 (pt)
EP (1) EP1696913B1 (pt)
JP (2) JP5226220B2 (pt)
KR (1) KR101166347B1 (pt)
CN (2) CN101695474A (pt)
AR (1) AR047346A1 (pt)
AT (1) ATE424201T1 (pt)
AU (1) AU2004314154B2 (pt)
BR (1) BRPI0418005B8 (pt)
CA (1) CA2551493C (pt)
CR (1) CR8473A (pt)
CY (1) CY1109120T1 (pt)
DE (1) DE602004019809D1 (pt)
DK (1) DK1696913T3 (pt)
EC (1) ECSP066663A (pt)
ES (1) ES2323374T3 (pt)
FR (1) FR2863891B1 (pt)
HK (1) HK1089105A1 (pt)
IL (1) IL176404A (pt)
MA (1) MA28237A1 (pt)
MX (1) MXPA06007208A (pt)
MY (1) MY139643A (pt)
NI (1) NI200600146A (pt)
NO (1) NO336427B1 (pt)
NZ (1) NZ548028A (pt)
OA (1) OA13348A (pt)
PL (1) PL1696913T3 (pt)
PT (1) PT1696913E (pt)
RU (1) RU2362557C2 (pt)
SI (1) SI1696913T1 (pt)
TN (1) TNSN06197A1 (pt)
TW (1) TWI334352B (pt)
UA (1) UA83888C2 (pt)
WO (1) WO2005070425A1 (pt)
ZA (1) ZA200605201B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2863891B1 (fr) * 2003-12-23 2006-03-24 Pf Medicament Composition pharmaceutique de vinflunine destinee a une administration parentale, procede de preparation et utilisation
US20110015221A1 (en) * 2003-12-23 2011-01-20 Pierre Fabre Medicament Pharmaceutical composition of vinflunine which is intended for parenteral administration preparation method thereof and use of same
FR2910812B1 (fr) * 2006-12-29 2009-03-20 Pierre Fabre Medicament Sa Compositions pharmaceutiques injectables lyophilisees de derives hemi-synthetiques d'alcaloide de vinca stables a temperature ambiante
FR2912406B1 (fr) * 2007-02-13 2009-05-08 Pierre Fabre Medicament Sa Sels cristalins anhydres de vinflunine, procede de preparation et utilisation en tant que medicament et moyen de purification de la vinflunine.
EP1997534A1 (en) * 2007-05-31 2008-12-03 Pierre Fabre Medicament Cancer treatment combination therapy comprising vinflunine and trastuzumab
CN101129374B (zh) * 2007-06-26 2010-09-08 齐鲁制药有限公司 长春氟宁药物组合物及其制备方法与应用
FR2918567B1 (fr) * 2007-07-11 2012-08-03 Pf Medicament Composition pharmaceutique stable d'un sel hydrosoluble de vinorelbine.
FR2918566B1 (fr) * 2007-07-11 2009-10-09 Pierre Fabre Medicament Sa Composition pharmaceutique stable d'un sel hydrosoluble de vinflunine.
CN101607968A (zh) * 2008-06-17 2009-12-23 江苏豪森药业股份有限公司 长春氟宁盐、其制备方法及其药物组合物
UY33975A (es) * 2011-03-29 2012-10-31 Sanofi Sa Formulaciones de otamixaban con estabilidad mejorada
ES2823281T3 (es) * 2015-08-01 2021-05-06 Sun Pharmaceutical Ind Ltd Forma de dosificación del fármaco alcaloide vinca
EP3481422A1 (en) * 2016-07-06 2019-05-15 Pierre Fabre Medicament Vinflunine and pd1 and/or pdl1 inhibitor as pharmaceutical combination

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4307100A (en) * 1978-08-24 1981-12-22 Agence Nationale De Valorisation De La Recherche (Anvar) Nor bis-indole compounds usable as medicaments
US4619935A (en) * 1983-03-17 1986-10-28 Eli Lilly And Company Stable oncolytic formulations
HU195513B (en) * 1984-10-16 1988-05-30 Richter Gedeon Vegyeszet Process for producing stable solutions of alkaloides with bis-indole skeleton
FR2597750B1 (fr) * 1986-04-25 1989-06-02 Pf Medicament Solution aqueuse stable de sulfate de vincristine
IL83086A (en) * 1987-07-06 1991-03-10 Teva Pharma Stable,injectable solutions of vincristine salts
US4923876A (en) * 1988-04-18 1990-05-08 Cetus Corporation Vinca alkaloid pharmaceutical compositions
CA2001643A1 (en) * 1988-12-23 1990-06-23 Richard L. Wolgemuth Preservative-free multi-dose vincristine solution
HU204995B (en) * 1989-11-07 1992-03-30 Richter Gedeon Vegyeszet Process for producing pharmaceutical composition comprising alkaloid with bis-indole skeleton, with antitumour activity and suitable fr parenteral purposes
JPH06100452A (ja) * 1993-04-06 1994-04-12 Asta Medica Ag イホスファミド用の製薬学的容器
FR2707988B1 (fr) * 1993-07-21 1995-10-13 Pf Medicament Nouveaux dérivés antimitotiques des alcaloïdes binaires du catharantus rosesus, leur procédé de préparation et les compositions pharmaceutiques les comprenant.
DE19706255C2 (de) * 1997-02-18 2000-11-30 Schott Glas Sterilisierbarer Glasbehälter für medizinische Zwecke, insbesondere zur Aufbewahrung pharmazeutischer oder diagnostischer Produkte
FR2761990B1 (fr) * 1997-04-10 1999-06-25 Pf Medicament Derives halogenes antimitotiques d'alcaloides de vinca
JP3642492B1 (ja) * 2003-10-31 2005-04-27 小野薬品工業株式会社 オザグレルナトリウム含有水溶液を充填してなる注射用容器
FR2863891B1 (fr) * 2003-12-23 2006-03-24 Pf Medicament Composition pharmaceutique de vinflunine destinee a une administration parentale, procede de preparation et utilisation

Also Published As

Publication number Publication date
MY139643A (en) 2009-10-30
ATE424201T1 (de) 2009-03-15
KR101166347B1 (ko) 2012-07-18
IL176404A0 (en) 2006-10-05
SI1696913T1 (sl) 2009-08-31
PT1696913E (pt) 2009-06-05
CR8473A (es) 2006-11-24
AU2004314154A1 (en) 2005-08-04
BRPI0418005B1 (pt) 2019-11-26
FR2863891B1 (fr) 2006-03-24
JP5226220B2 (ja) 2013-07-03
TNSN06197A1 (fr) 2007-11-15
CA2551493A1 (fr) 2005-08-04
NZ548028A (en) 2010-01-29
PL1696913T3 (pl) 2009-08-31
EP1696913B1 (fr) 2009-03-04
OA13348A (fr) 2007-04-13
CN101695474A (zh) 2010-04-21
JP5710462B2 (ja) 2015-04-30
TW200531717A (en) 2005-10-01
JP2012102120A (ja) 2012-05-31
JP2007515461A (ja) 2007-06-14
WO2005070425A1 (fr) 2005-08-04
ECSP066663A (es) 2006-10-25
NO20063277L (no) 2006-07-14
EP1696913A1 (fr) 2006-09-06
NO336427B1 (no) 2015-08-17
HK1089105A1 (en) 2006-11-24
FR2863891A1 (fr) 2005-06-24
DK1696913T3 (da) 2009-06-29
ZA200605201B (en) 2007-09-26
DE602004019809D1 (de) 2009-04-16
ES2323374T3 (es) 2009-07-14
RU2006126708A (ru) 2008-01-27
AR047346A1 (es) 2006-01-18
IL176404A (en) 2010-11-30
CA2551493C (fr) 2012-12-04
TWI334352B (en) 2010-12-11
MA28237A1 (fr) 2006-10-02
UA83888C2 (ru) 2008-08-26
NI200600146A (es) 2006-12-12
AU2004314154B2 (en) 2011-03-24
RU2362557C2 (ru) 2009-07-27
US20070155768A1 (en) 2007-07-05
KR20060124624A (ko) 2006-12-05
MXPA06007208A (es) 2006-08-18
CN1897940A (zh) 2007-01-17
BRPI0418005B8 (pt) 2021-05-25
CY1109120T1 (el) 2014-07-02

Similar Documents

Publication Publication Date Title
BRPI0418005A (pt) composição farmacêutica de vinflunina, utilização de uma composição, processo de preparação de uma composição e recipiente de acondicionamento
BRPI0409198A (pt) derivados quinolin-2-ona para o tratamento de doenças de vias aéreas
RS53418B (en) PHARMACEUTICALS, ACTION PROCESSING AND THERAPEUTIC USES
DE69735851D1 (de) Verfahren zur aktivierung von menschlichen, antigen-aktivierenden zellen, aktivierte menschliche, antigen-aktivierende zellen und anwendungen derselben
AU2002314914A1 (en) Hydroxy alkyl amine derivatives as beta-secretase inhibitors and their use for the treatment of alzheimer's disease and similar diseases
MY162640A (en) Thioninium compounds and their use
BRPI0407662B8 (pt) derivados do ácido 1-fenilalcanocarboxílico para o tratamento de doenças neurodegenerativas
CU23367A3 (es) Formulación de moxifloxacino con sal común
BRPI0518231A2 (pt) derivados de 2-amido-4-feniltiazol, o respectivo preparo e a respectiva aplicaÇço em terapÊutica
SE0300098D0 (sv) Use of cyclin D1 inhibitors
MX2008002065A (es) Derivados de pirazola como agentes terapeuticos.
AR063927A1 (es) Procedimiento para la preparacion de 4, 4' -(1-metil-1,2-etandil)-bis- (2,6 -piperazindiona)
UA88481C2 (ru) Донепезила фумарат, пригодный для получения фармацевтических композиций
SE0402507D0 (sv) Medicinsk lösning, förfarande för framställning och användning därav
CY1106950T1 (el) Μονοενυδρο αλας νατριου της s-tενατοπραζολης και εφαρμογη υπο τυπον αναστολεα αντλιας πρωτονιων
ATE440835T1 (de) Heterozyklische harnstoff-derivate für die behandlung von schmerzen.
TW200635925A (en) Aminium salts of 1,2,3-triazoles as prodrugs of drugs including antiviral agents
EA200701797A1 (ru) Соли окаперидона и фармацевтические композиции, содержащие указанные соли
GB0229022D0 (en) Organic Compounds
ATE441461T1 (de) Mittel zur behandlung von infektionen
RU2006133875A (ru) Способ лечения пародонтита
TH70518A (th) สารประกอบชนิดใหม่
SE0400522D0 (sv) A medical solution, a method for producing said medical solution and use thereof
BRPI0601884A (pt) composição farmacêutica aplicável na terapêutica da doença de peyronie e respectivo processo de obtenção
MX2009005750A (es) N,n,n',n'-tetraquis(2-cloroetil)-fosforodiamidatos de 2-{[2-amino substituido)etil]-sulfonil}etilo.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 26/11/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 26/11/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/12/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF